Department of Ophthalmology III, Quinze-Vingts National Ophtalmology Hospital, IHU FOReSIGHT.
Department of Ophthalmology, Ambroise Paré Hospital, APHP, France, Paris Saclay University, Saclay.
J Glaucoma. 2023 Dec 1;32(12):1052-1057. doi: 10.1097/IJG.0000000000002327. Epub 2023 Oct 19.
The iStent inject W implanted during phacoemulsification effectively reduces IOP.
The purpose of this study was to evaluate the efficacy and safety of iStent inject W combined with phacoemulsification in patients with controlled open angle glaucoma undergoing cataract surgery.
We conducted a retrospective, bicentric study of patients with controlled chronic open angle glaucoma who underwent phacoemulsification combined with the injection of 2 iStent inject Ws. Patient characteristics, including intraocular pressure (IOP) and the number of glaucoma medications, were evaluated preoperatively and 1 week, 1 month, and 6 months postoperatively. The primary end point was IOP reduction, and the secondary end point was the reduction in the number of glaucoma medications.
In this study, 85 eyes were included. The majority of patients had primary open angle glaucoma (85% of eyes). Preoperative mean IOP was 16.1±2.0 mm Hg with a mean of 2.3±0.5 glaucoma medications. At 1 week postoperatively, the mean IOP was 16.7±3.1 mm Hg with a mean of 2.0±0.7 hypotensive medications. At 1 and 6 months, the mean IOP was 14.2±2.1 and 13.0±1.5 mm Hg, with a mean of 2.0±0.6 and 1.8±0.5 glaucoma medications, respectively. The percentage IOP reduction at 1 and 6 months was 11.6% ( P =0.001) and 19.3% ( P <0.0001), respectively. Regarding glaucoma medications, at 1 and 6 months, the reduction in the number of medications was 12.9% ( P =0.025) and 22.4% ( P =0.003), respectively. The most frequent significant postoperative adverse events were corneal edema in 7%, IOP spikes in 6%, and hyphema in 6% of eyes, which resolved spontaneously.
The iStent inject W implanted during phacoemulsification effectively reduces IOP and the number of glaucoma medications needed at 6 months of follow-up, with a favorable safety profile in patients with controlled open angle glaucoma.
在超声乳化白内障吸除术中植入的 iStent inject W 可有效降低眼压。
本研究旨在评估 iStent inject W 联合超声乳化白内障吸除术治疗接受白内障手术的控制型开角型青光眼患者的疗效和安全性。
我们进行了一项回顾性、双中心研究，纳入了 85 例接受超声乳化白内障吸除术联合注射 2 枚 iStent inject W 的控制型慢性开角型青光眼患者。评估了患者的特征，包括眼压（IOP）和青光眼药物的数量，分别于术前及术后 1 周、1 个月和 6 个月进行。主要终点为眼压降低，次要终点为青光眼药物数量减少。
在这项研究中，共纳入 85 只眼。大多数患者为原发性开角型青光眼（85%的眼）。术前平均 IOP 为 16.1±2.0 mmHg，平均使用 2.3±0.5 种降眼压药物。术后 1 周时，平均 IOP 为 16.7±3.1 mmHg，平均使用 2.0±0.7 种降压药物。术后 1 个月和 6 个月时，平均 IOP 分别为 14.2±2.1mmHg 和 13.0±1.5mmHg，平均使用 2.0±0.6 种和 1.8±0.5 种青光眼药物。术后 1 个月和 6 个月时的 IOP 降低百分比分别为 11.6%（P=0.001）和 19.3%（P<0.0001）。关于青光眼药物，术后 1 个月和 6 个月时，药物数量减少了 12.9%（P=0.025）和 22.4%（P=0.003）。术后最常见的显著不良事件为 7%的角膜水肿、6%的眼压升高和 6%的前房积血，均自行缓解。
在超声乳化白内障吸除术中植入的 iStent inject W 可有效降低眼压和术后 6 个月所需的青光眼药物数量，在控制型开角型青光眼患者中具有良好的安全性。
Zotero 插件